These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10959687)

  • 1. Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy.
    Aukrust P; Bjørnsen S; Lunden B; Otterdal K; Ng EC; Ameln W; Ueland T; Müller F; Solum NO; Brosstad F; Frøland SS
    Thromb Haemost; 2000 Aug; 84(2):183-7. PubMed ID: 10959687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble adhesion molecules and endothelial cell damage in HIV infected patients.
    Seigneur M; Constans J; Blann A; Renard M; Pellegrin JL; Amiral J; Boisseau M; Conri C
    Thromb Haemost; 1997 Apr; 77(4):646-9. PubMed ID: 9134636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormally large von Willebrand factor multimers in Henoch-Schönlein purpura.
    Casonato A; Pontara E; Bertomoro A; Ossi E; Vincenti M; Girolami A; Borsatti A; Bertaglia G
    Am J Hematol; 1996 Jan; 51(1):7-11. PubMed ID: 8571941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia.
    Ferro D; Quintarelli C; Lattuada A; Leo R; Alessandroni M; Mannucci PM; Violi F
    Hepatology; 1996 Jun; 23(6):1377-83. PubMed ID: 8675154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of two von Willebrand factor collagen-binding assays with different binding affinities for low, medium, and high multimers of von Willebrand factor.
    Neugebauer BM; Goy C; Budek I; Seitz R
    Semin Thromb Hemost; 2002 Apr; 28(2):139-48. PubMed ID: 11992237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to brain natriuretic peptide and outcomes.
    Chong AY; Freestone B; Patel J; Lim HS; Hughes E; Blann AD; Lip GY
    Am J Cardiol; 2006 Mar; 97(5):671-5. PubMed ID: 16490435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet von Willebrand factor determination does not improve the diagnosis of patients with suspected Type 1 von Willebrand disease.
    Shihong I; Morris D; Konkle BA
    Haemophilia; 2009 Jan; 15(1):131-4. PubMed ID: 18976254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial.
    Varughese GI; Patel JV; Tomson J; Blann AD; Hughes EA; Lip GY
    J Intern Med; 2007 Apr; 261(4):384-91. PubMed ID: 17391113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant von Willebrand factor-insight into structure and function through infusion studies in animals with severe von Willebrand disease.
    Schwarz HP; Schlokat U; Mitterer A; Váradi K; Gritsch H; Muchitsch EM; Auer W; Pichler L; Dorner F; Turecek PL
    Semin Thromb Hemost; 2002 Apr; 28(2):215-26. PubMed ID: 11992244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cold storage of citrated whole blood induces drastic time-dependent losses in factor VIII and von Willebrand factor: potential for misdiagnosis of haemophilia and von Willebrand disease.
    Böhm M; Täschner S; Kretzschmar E; Gerlach R; Favaloro EJ; Scharrer I
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):39-45. PubMed ID: 16607078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic heart failure: the Frederiksberg heart failure study.
    Chong AY; Freestone B; Lim HS; Kistorp C; Gustafsson F; Hildebrandt P; Lip GY
    Int J Cardiol; 2007 Jun; 119(1):80-2. PubMed ID: 17027106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.